Drug intelligence / Profile preview

Anti-SARS-CoV-2 mRNA vaccine

Development stage: Preclinical
Lead developer: Flag Bio
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

Anti-SARS-CoV-2 mRNA vaccine is a preclinical-stage vaccine candidate developed by Flag Bio for the prevention of COVID-19. The vaccine utilizes synthetic mRNA technology to encode SARS-CoV-2 antigens, which are expressed in host cells to stimulate a protective immune response. A distinguishing feature of Flag Bio's platform is the potential co-administration with Flag-711, a proprietary synthetic mRNA adjuvant that encodes a flagellin protein to act as a Toll-like receptor 5 (TLR5) agonist. This combination is intended to enhance the magnitude and duration of the immune response. Flag Bio is also exploring alternative delivery routes through partnerships in mRNA formulation technology.

Other names: COVID-19 mRNA vaccineCOVID19 mRNA vaccineCOVID 19 mRNA vaccine

Targets

SARS-CoV-2 spikeTLR5

Beyond the preview

Go deeper on Anti-SARS-CoV-2 mRNA vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anti-SARS-CoV-2 mRNA vaccine.

Explore the full profile